<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098501</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01459</org_study_id>
    <secondary_id>MC027C</secondary_id>
    <secondary_id>NCI-6200</secondary_id>
    <secondary_id>MAYO-MC027C</secondary_id>
    <secondary_id>CDR0000398176</secondary_id>
    <secondary_id>U01CA069912</secondary_id>
    <nct_id>NCT00098501</nct_id>
  </id_info>
  <brief_title>CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Trial of CCI-779 in Combination With EKB-569, an EGFR Inhibitor, in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects, best way to give, and best dose of CCI-779&#xD;
      and EKB-569 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such&#xD;
      as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. EKB-569 may stop the growth of tumor cells by&#xD;
      blocking some of the enzymes needed for their growth. Giving CCI-779 together with EKB-569&#xD;
      may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of the combination of CCI-779 and EKB-569 in patients&#xD;
      with advanced solid tumors.&#xD;
&#xD;
      II. Determine the toxicity of this regimen in these patients. III. Determine the response&#xD;
      rate in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 3 treatment groups.&#xD;
&#xD;
      Group I: Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of EKB-569 and CCI-779 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Group II: Patients receive oral EKB-569 at the MTD on days 4-28 of course 1 and days 1-28 of&#xD;
      all subsequent courses and CCI-779 at the MTD on days 1-3 and 15-17.&#xD;
&#xD;
      Group III: Patients receive EKB-569 at the MTD as in group I and oral CCI-779 at the MTD on&#xD;
      days 7-9 and 19-21 of course 1 and days 1-3 and 15-17 of all subsequent courses.&#xD;
&#xD;
      In all groups, courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-42 patients (18-30 for group I, 6 for group II, and 6 for&#xD;
      group III) will be accrued for this study within 1.35-1.75 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of all adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0</measure>
    <time_frame>Up to 30 days after last dose of study treatment</time_frame>
    <description>Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best response according to the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Time from the start of the treatment until disease progression/recurrence, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until any treatment related toxicity</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until treatment related grade 3+ toxicity</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hematologic nadirs (white blood cells [WBC], absolute neutrophil count [ANC], platelets)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pelitinib</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>EKB-569</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unresectable solid tumor for which there is no known standard&#xD;
             therapy that is potentially curative or capable of extending life expectancy&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST ≤ 3 times upper limit of normal (ULN) (5 times ULN if liver involvement)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  Fasting cholesterol &lt; 350 mg/dL&#xD;
&#xD;
          -  Fasting triglycerides &lt; 400 mg/dL&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic colony-stimulating factor therapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent oral contraceptives&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 30% of bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  More than 7 days since prior CYP3A4 inducers&#xD;
&#xD;
          -  No prior mTOR-targeting agents&#xD;
&#xD;
          -  No prior epidermal growth factor receptor-targeting agents&#xD;
&#xD;
          -  No concurrent antiretroviral therapy that induces or inhibits CYP3A4 for HIV-positive&#xD;
             patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Erlichman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>EKB 569</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

